Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ajit G Thomas

Showing results (31-40 of 80) with videos related to

Pageof 8
Sort By:
RSC Advances|March 29, 2021
An efficient synthetic route to l-γ-methyleneglutamine and its amide derivatives, and their selective anticancer activityMd Imran Hossain, Ajit G Thomas, Fakhri Mahdi, et al.
Pharmaceutics|October 27, 2022
D-DOPA Is a Potent, Orally Bioavailable, Allosteric Inhibitor of Glutamate Carboxypeptidase IISadakatali S Gori, Ajit G Thomas, Arindom Pal, et al.
British Journal of Pharmacology|July 6, 2019
A novel and potent brain penetrant inhibitor of extracellular vesicle releaseCamilo Rojas, Michal Sala, Ajit G Thomas, et al.
Journal of Medicinal Chemistry|August 5, 2022
Discovery of Orally Bioavailable and Brain-Penetrable Prodrugs of the Potent nSMase2 Inhibitor DPTIPArindom Pal, Sadakatali Gori, Seung-Wan Yoo, et al.
Biochemical Pharmacology|October 22, 2021
Inhibition of neutral sphingomyelinase 2 reduces extracellular vesicle release from neurons, oligodendrocytes, and activated microglial cells following acute brain injuryCarolyn Tallon, Silvia Picciolini, Seung-Wan Yoo, et al.
Journal of Alzheimer'S Disease : JAD|July 18, 2020
Glutamine Antagonist JHU-083 Normalizes Aberrant Hippocampal Glutaminase Activity and Improves Cognition in APOE4 MiceKristen R Hollinger, Xiaolei Zhu, Elizabeth S Khoury, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 5, 2017
Local enema treatment to inhibit FOLH1/GCPII as a novel therapy for inflammatory bowel diseaseAbhijit A Date, Rana Rais, Taarika Babu, et al.
Bioorganic & Medicinal Chemistry|October 17, 2020
Allosteric kidney-type glutaminase (GLS) inhibitors with a mercaptoethyl linkerBridget Duvall, Sarah C Zimmermann, Run-Duo Gao, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 9, 2018
Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney diseaseIrfana Soomro, Ying Sun, Zhai Li, et al.
JCI Insight|August 19, 2016
<i>FOLH1</i>/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalitiesRana Rais, Weiwei Jiang, Huihong Zhai, et al.
Pageof 8

Showing results (31-40 of 80) with videos related to

Sort By:
Pageof 8
RSC Advances|March 29, 2021
An efficient synthetic route to l-γ-methyleneglutamine and its amide derivatives, and their selective anticancer activityMd Imran Hossain, Ajit G Thomas, Fakhri Mahdi, et al.
Pharmaceutics|October 27, 2022
D-DOPA Is a Potent, Orally Bioavailable, Allosteric Inhibitor of Glutamate Carboxypeptidase IISadakatali S Gori, Ajit G Thomas, Arindom Pal, et al.
British Journal of Pharmacology|July 6, 2019
A novel and potent brain penetrant inhibitor of extracellular vesicle releaseCamilo Rojas, Michal Sala, Ajit G Thomas, et al.
Journal of Medicinal Chemistry|August 5, 2022
Discovery of Orally Bioavailable and Brain-Penetrable Prodrugs of the Potent nSMase2 Inhibitor DPTIPArindom Pal, Sadakatali Gori, Seung-Wan Yoo, et al.
Biochemical Pharmacology|October 22, 2021
Inhibition of neutral sphingomyelinase 2 reduces extracellular vesicle release from neurons, oligodendrocytes, and activated microglial cells following acute brain injuryCarolyn Tallon, Silvia Picciolini, Seung-Wan Yoo, et al.
Journal of Alzheimer'S Disease : JAD|July 18, 2020
Glutamine Antagonist JHU-083 Normalizes Aberrant Hippocampal Glutaminase Activity and Improves Cognition in APOE4 MiceKristen R Hollinger, Xiaolei Zhu, Elizabeth S Khoury, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 5, 2017
Local enema treatment to inhibit FOLH1/GCPII as a novel therapy for inflammatory bowel diseaseAbhijit A Date, Rana Rais, Taarika Babu, et al.
Bioorganic & Medicinal Chemistry|October 17, 2020
Allosteric kidney-type glutaminase (GLS) inhibitors with a mercaptoethyl linkerBridget Duvall, Sarah C Zimmermann, Run-Duo Gao, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 9, 2018
Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney diseaseIrfana Soomro, Ying Sun, Zhai Li, et al.
JCI Insight|August 19, 2016
<i>FOLH1</i>/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalitiesRana Rais, Weiwei Jiang, Huihong Zhai, et al.
Pageof 8